Market Place
Sourcing Support
BeOne Medicines to Report Q1 2026 Results on May 6
22 Apr 2026 //
BUSINESSWIRE
Beone Medicines To Present At Upcoming Investor Conferences
17 Feb 2026 //
BUSINESSWIRE
BeOne Medicines To Release 2025 Q4 And Full-Year Financials
11 Feb 2026 //
BUSINESSWIRE
InSysBio to Announce a Collaborative Project with BeOne Medicines
28 Jan 2026 //
PR NEWSWIRE
Beone Medicines To Present At J.P. Morgan Healthcare Conference
23 Dec 2025 //
BUSINESSWIRE
BeOne Medicines Reveals Q3 2025 Financials & Business Updates
06 Nov 2025 //
BUSINESSWIRE
Beone Medicines To Present At Upcoming Investor Conferences
28 Oct 2025 //
BUSINESSWIRE
Beone Medicines To Release Q3 2025 Financial Results On Nov 6
22 Oct 2025 //
BUSINESSWIRE
Abbvie, Beone End BTK Inhibitor Patent Fight
02 Oct 2025 //
FIERCE PHARMA
BeOne Medicines Reveals Q2 2025 Financial Results & Updates
06 Aug 2025 //
BUSINESSWIRE
BeOne Gets PRIME Designation for BGB-16673 in Macroglobulinemia
31 Jul 2025 //
BUSINESSWIRE
Be One`s Tevimbra Gets Positive Chmp Opinion for NSCLC Treatment
28 Jul 2025 //
BUSINESSWIRE
BeOne Medicines` Q2 2025 Financial Results Due August 6
16 Jul 2025 //
BUSINESSWIRE
Biocytogen, BeOne Ink Antibody Licensing Deal
09 Jul 2025 //
BUSINESSWIRE
U.S. Fda Approves Tablet Formulation of Brukinsa
11 Jun 2025 //
BUSINESSWIRE
BeOne Medicines to Host Investor R&D Day Webcast on June 26, 2025
11 Jun 2025 //
BUSINESSWIRE
Glenmark Pharma to launch DCGI-approved Brukinsa in India
11 Jun 2025 //
INDPHARMAPOST
BeiGene Gets CHMP Nod for Tevimbra in Nasopharyngeal Cancer
27 May 2025 //
BUSINESSWIRE
BeiGene Presents Cancer Research at ASCO 2025
22 May 2025 //
BUSINESSWIRE
BeiGene Highlights Hematology Portfolio at EHA 2025
14 May 2025 //
BUSINESSWIRE
BeiGene to Present at RBC Healthcare Conference
13 May 2025 //
BUSINESSWIRE
BeiGene Announces Q1 2025 Financial Results and Business Updates
07 May 2025 //
BUSINESSWIRE
US Patent Office Invalidates Pharmacyclics Patent Against BeiGene
29 Apr 2025 //
BUSINESSWIRE
BeiGene Announces Q4 & Full Year 2024 Financial Results & Updates
27 Feb 2025 //
BUSINESSWIRE
BeiGene to Present at Upcoming Investor Conferences
25 Feb 2025 //
BUSINESSWIRE
BeiGene to Announce Q4 & Full Year 2024 Financial Results on Feb 27
13 Feb 2025 //
BUSINESSWIRE
FleishmanHillard finds new managing director of health, life sci
08 Jan 2025 //
FIERCE PHARMA
BeiGene Names Giancarlo Benelli As Head Of Europe Operations
06 Jan 2025 //
BUSINESSWIRE
BeiGene Changes Nasdaq Ticker to "ONC" on Jan 2, to Present at JPM
23 Dec 2024 //
BUSINESSWIRE
BeiGene Advances Leadership in CLL with Brukinsa & Pipeline Data
09 Dec 2024 //
BUSINESSWIRE
BeiGene to Host Webcast on Data from ASH & SABCS on Dec. 16, 2024
02 Dec 2024 //
BUSINESSWIRE
BeiGene to Present at Upcoming Investor Conferences
26 Nov 2024 //
BUSINESSWIRE
BeiGene proposes new name, reaffirming oncology mission
15 Nov 2024 //
EUROPEAN PHARMACEUTICAL REVIEW
BeiGene Announces Q3 2024 Financial Results and Corporate Updates
12 Nov 2024 //
BUSINESSWIRE
BeiGene to Present at the Jefferies London Healthcare Conference
06 Nov 2024 //
BUSINESSWIRE
BeiGene Highlights Hematology Portfolio at ASH 2024
05 Nov 2024 //
BUSINESSWIRE
BeiGene Mourns Death of Beloved Board Member Donald Glazer
28 Oct 2024 //
BUSINESSWIRE
BeiGene Appoints Shalini Sharp To Board Of Directors
26 Sep 2024 //
BUSINESSWIRE
FDA challenges broad use of PD-1 drugs in stomach cancer
24 Sep 2024 //
FIERCE PHARMA
AbbVie Sues BeiGene Over BTK Degrader Trade Secrets
11 Sep 2024 //
FIERCE BIOTECH
AbbVie sues rival BeiGene over alleged theft of cancer therapy secrets
10 Sep 2024 //
REUTERS
BeiGene Sponsors Leukemia & Lymphoma Society Campaign
05 Sep 2024 //
FIERCE PHARMA
BeiGene To Present At Morgan Stanley Healthcare Conference
28 Aug 2024 //
BUSINESSWIRE
BeiGene’s BGB-16673 Receives U.S. FDA Fast Track Designation for CLL/SLL
26 Aug 2024 //
BUSINESSWIRE
BeiGene Reports Q2 2024 Results And Enters Next Global Growth Phase
07 Aug 2024 //
BUSINESSWIRE
BeiGene Enters Next Phase of Global Growth with Announcement of Second Quarter 2024
07 Aug 2024 //
PRESS RELEASE
BeiGene Announces Appointment of Aaron Rosenberg as Chief Financial Officer
18 Jul 2024 //
BUSINESSWIRE
BeiGene To Present BRUKINSA Plus Venetoclax CLL SLL Data
14 Jun 2024 //
BUSINESSWIRE
Ensem’s partner BeiGene doses first five patients in first-in-human phase 1 tria
14 Jun 2024 //
PHARMABIZ
BeiGene & NewBridge Pharmaceuticals FZ LLC Mutually Agree to Conclude BRUKINSA
13 Jun 2024 //
BUSINESSWIRE
BeiGene to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
04 Jun 2024 //
BUSINESSWIRE
Brukinsa® Cll Sll Profile: Differentiated Clinical Data At Asco
24 May 2024 //
BUSINESSWIRE
BeiGene looks at new partnerships,with full cancer pipeline & growing footprint
15 May 2024 //
ENDPTS
BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024
14 May 2024 //
BUSINESSWIRE
BeiGene Reports First Quarter 2024 Financial Results and Business Updates
08 May 2024 //
BUSINESSWIRE
BeiGene earmarks $74M to build fourth facility in China
08 May 2024 //
ENDPTS
BeiGene`s 2023 Responsible Business & Sustainability Report
26 Apr 2024 //
BUSINESSWIRE
BeiGene Highlights New Hematology & Solid Tumor Data at ASCO 2024
24 Apr 2024 //
BUSINESSWIRE
US FDA approves BeiGene`s esophageal cancer therapy
15 Mar 2024 //
REUTERS
First Doses of BRUKINSA® provided to Patients with Chronic Lymphocytic Leukemia
13 Mar 2024 //
BUSINESSWIRE
